These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

63 related items for PubMed ID: 19481602

  • 1. Physicochemical and pharmacological characterization of novel vasoactive intestinal peptide derivatives with improved stability.
    Onoue S, Misaka S, Ohmori Y, Sato H, Mizumoto T, Hirose M, Iwasa S, Yajima T, Yamada S.
    Eur J Pharm Biopharm; 2009 Sep; 73(1):95-101. PubMed ID: 19481602
    [Abstract] [Full Text] [Related]

  • 2. Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
    Onoue S, Endo K, Ohmori Y, Yamada S, Kimura R, Yajima T, Kashimoto K.
    Regul Pept; 2004 Dec 15; 123(1-3):193-9. PubMed ID: 15518912
    [Abstract] [Full Text] [Related]

  • 3. Novel vasoactive intestinal peptide derivatives with improved stability protect rat alveolar L2 cells from cigarette smoke-induced cytotoxicity and apoptosis.
    Misaka S, Sato H, Aoki Y, Mizumoto T, Onoue S, Yamada S.
    Peptides; 2011 Feb 15; 32(2):401-7. PubMed ID: 20977915
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhalable sustained-release formulation of long-acting vasoactive intestinal peptide derivative alleviates acute airway inflammation.
    Onoue S, Matsui T, Kuriyama K, Ogawa K, Kojo Y, Mizumoto T, Karaki S, Kuwahara A, Yamada S.
    Peptides; 2012 Jun 15; 35(2):182-9. PubMed ID: 22484228
    [Abstract] [Full Text] [Related]

  • 10. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD.
    Onoue S, Yamada S, Yajima T.
    Peptides; 2007 Sep 15; 28(9):1640-50. PubMed ID: 17537541
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability.
    Dangoor D, Biondi B, Gobbo M, Vachutinski Y, Fridkin M, Gozes I, Rocchi R.
    J Pept Sci; 2008 Mar 15; 14(3):321-8. PubMed ID: 17924396
    [Abstract] [Full Text] [Related]

  • 13. Respirable powder formulation of a shortened vasoactive intestinal peptide analog for treatment of airway inflammatory diseases.
    Suzuki H, Mizumoto T, Seto Y, Sato H, Onoue S.
    J Pept Sci; 2018 Mar 15; 24(3):. PubMed ID: 29441631
    [Abstract] [Full Text] [Related]

  • 14. Radiolabeling and in vitro and in vivo characterization of [18F]FB-[R(8,15,21), L17]-VIP as a PET imaging agent for tumor overexpressed VIP receptors.
    Cheng D, Yin D, Li G, Wang M, Li S, Zheng M, Cai H, Wang Y.
    Chem Biol Drug Des; 2006 Dec 15; 68(6):319-25. PubMed ID: 17177894
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma.
    Bolin DR, Michalewsky J, Wasserman MA, O'Donnell M.
    Biopolymers; 1995 Dec 15; 37(2):57-66. PubMed ID: 7893947
    [Abstract] [Full Text] [Related]

  • 20. Novel extended and branched N-terminal analogs of VIP.
    Dangoor D, Rubinraut S, Fridkin M, Gozes I.
    Regul Pept; 2006 Nov 15; 137(1-2):42-9. PubMed ID: 16962672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.